S
uccessful reduction of cardiovascular disease (CVD) risk among people with diabetes mellitus is increasingly reliant on combination pharmacotherapy targeting its major risk factors, especially hypertension and high cholesterol level. 1 The impact of tight hyperglycemia control on CVD and mortality risk is currently unclear, but its control is a major part of comprehensive diabetes care and is also increasingly attained through combination therapy. [2] [3] [4] We sought to examine the competing treatment priorities for US adults with diabetes by analyzing the use of antidiabetes, antihypertensive, and statin medications over time from the populationbased National Health and Nutrition Examination Survey (NHANES) between 1999 and 2006.
Methods. NHANES 1999 NHANES -2000 NHANES , 2001 NHANES -2002 NHANES , 2003 NHANES -2004 NHANES , and 2005 NHANES -2006 are serial cross-sectional surveys including nationally representative samples of the noninstitutionalized civilian US population identified through a stratified, multistage probability sampling design. 5 The present analysis was limited to adults 20 years and older, who reported a history of diabetes mellitus. Data were collected through questionnaires (demographics and medical history), a physical examination (blood pressure), and blood collection (lipid, glucose, and hemoglobin A 1c [HbA 1c ] levels). Use of antidiabetes, antihypertensive, and statin medications was ascertained via a series of questions about prescription medicines taken during the previous month and medication container examination.
The American Diabetes Association guidelines for standard medical care were used to determine the eligibility of participants with diabetes for antidiabetes, antihypertensive, and statin medications. 2 Results. Over the 8-year study period there was a significant decline in HbA 1c , SBP, and total cholesterol levels among those with diabetes (Table) The use of antidiabetes medications substantially exceeded the proportion of eligible adults with diabetes taking antihypertensives and statins. The higher use of antidiabetes medications may be why the proportion of those with diabetes achieving an HbA 1c level lower than 7% was 50% and 35% greater than those achieving hypertension and cholesterol control, respectively. The present data also substantiate reports of increasing use of combined antidiabetes medication therapy, a decline in older generation oral medications such as sulfonylureas, and the rising use of the metformin and thiazolidinedione classes. 6 The higher rates of antidiabetes medications compared with antihypertensive and statin medications highlights the concerns that a disproportionate emphasis is placed on controlling hyperglycemia at the expense of the more evidence-based CVD risk reduction strategies of controlling hypertension and high cholesterol level. 7, 8 Although research on competing priorities is limited, our study extends this literature by documenting that patients with diabetes are more likely to receive antidiabetes medication, which have not been shown to reduce CVD risk, rather than antihypertensive medications or statins. 7, 9 Whether this phenomena is due to physician or patient preference is not discernable from our data.
Prior to landmark studies such as Action to Control Cardiovascular Risk in Diabetes (ACCORD) 3 and Action in Diabetes and Vascular Disease (ADVANCE), 4 published in 2008, there was wide support for tight glucose control. The impact of these new data on clinical practice has yet to be determined. Studies such as Steno- 2 10 that highlight the mortality benefit of aggressive hypertension and cholesterol control, along with our data, should encourage a renewed emphasis of their control among patients with diabetes.
Between 1999-2000 and 2005-2006, improvements occurred in the control of hyperglycemia, hypertension, and high cholesterol level among US adults with diabetes. Also, there was increasingly aggressive medication use with substantially more combination therapy in antidiabetes medications and use of newer agents. The data from this study support the perception that control of hyperglycemia frequently takes precedence over control of hypertension and high cholesterol level among adults with diabetes. These observations support the argument for a reprioritization of diabetes treatment goals emphasizing hypertension and cholesterol control before tight glycemic control as part of an evidence-based global CVD risk reduction effort. 
Population-Based Surveillance of Infectious Endocarditis in an Italian Region

I
n a recent article, Murdoch and coworkers 1 report on a prospective cohort of 2781 adults with definite infectious endocarditis (IE), admitted to 58 hospitals in 25 countries from June 1, 2000, through September 1, 2005. As they acknowledge, one major limitation of the study is the "catchment area" of enrolled patients, namely centers with a particular interest in IE, typically referral centers with cardiac surgical programs. Admittedly, the study population was unlikely to be a true population-based sample, thereby limiting epidemiologic inferences. This is a common issue in most literature regarding IE. 2 Based on this concern, in 2004, we started a continuous surveillance of all cases of IE in our region, FriuliVenezia Giulia (FVG) (population 1 200 000) in Italy. 3 We report herein the methods used and preliminary results.
Methods. All 29 clinical centers potentially admitting cases of IE in FVG participated in the study ( Table 1) . The centers comprised general medicine wards (n=16), cardiology wards and their echocardiography service (n=9), and wards for infectious diseases (n=2) and cardiovascular surgery (n=2). Prior to study start, each center obtained ethics committee clearance. To ensure commit- 
